Company description

CTMX, also known as CytomX Therapeutics, is a biopharmaceutical company that specializes in developing antibody-based therapies for the treatment of cancer and other serious diseases. The company was founded in 2008 and is headquartered in South San Francisco, California. Their innovative approach combines expertise in protein engineering, cell biology, and computational biology to create novel treatments that target specific tumor markers. CTMX's proprietary Probody platform has the potential to significantly improve the safety and efficacy of cancer therapies by minimizing off-target effects. The company has multiple collaborations with leading pharmaceutical companies, including Bristol-Myers Squibb and Amgen, to develop and commercialize their Probody therapeutics. With a strong portfolio of product candidates in various stages of clinical development, CTMX is well-positioned to make a significant impact on the treatment of cancer and other diseases. Their dedication to advancing science and improving patient outcomes has garnered recognition and support from the scientific community and investors alike. CTMX continues to make strides in the biopharmaceutical industry, driven by a talented team and a deep commitment to transforming the lives of patients.